Abstract Number: 319 • 2013 ACR/ARHP Annual Meeting
Secukinumab Shows Substantial Improvement In Both Psoriasis Symptoms and Physical Functioning In Moderate-To-Severe Plaque Psoriasis Patients With Psoriatic Arthritis: A Subanalysis Of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Background/Purpose: Since interleukin (IL)-17A has a potential role in the pathogenesis and chronic inflammation of psoriatic disease, with similar pathways impacting skin and joints, strategies…Abstract Number: 815 • 2013 ACR/ARHP Annual Meeting
Long-Term (52-Week) Results Of a Phase 3, Randomized, Controlled Trial Of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, In Patients With Psoriatic Arthritis (PALACE 2)
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. PALACE 2 compared the efficacy and safety of APR…Abstract Number: 107 • 2013 ACR/ARHP Annual Meeting
Duration Of Symptoms Before Diagnosis In Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Background/Purpose: Early diagnosis is important for the treatment of many rheumatic diseases. Little is known about the duration of symptoms before establishment of diagnosis, and if the…Abstract Number: 816 • 2013 ACR/ARHP Annual Meeting
Apremilast, An Oral Phosphodiesterase 4 Inhibitor, Is Associated With Long-Term (52-Week) Improvements In Enthesitis and Dactylitis In Patients With Psoriatic Arthritis: Pooled Results From Three Phase 3, Randomized, Controlled Trials
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, works intracellularly to modulate pro- and anti-inflammatory mediators. The PALACE 1, 2, and 3 trials compared the…Abstract Number: L4 • 2013 ACR/ARHP Annual Meeting
Apremilast in the Treatment of DMARD-Naïve Psoriatic Arthritis Patients: Results of a Phase 3 Randomized, Controlled Trial (PALACE 4)
Background/Purpose: Apremilast (APR), an oral PDE4 inhibitor, works intracellularly to modulate inflammatory mediators. PALACE 4 compared APR with placebo (PBO) in DMARD-naïve patients (pts) with…Abstract Number: 818 • 2013 ACR/ARHP Annual Meeting
HLA-B*0801 Is Strongly Associated With Asymmetrical Sacroiliitis and HLA-B*27 With Symmetrical Involvement In Psoriatic Arthritis: Results Of a Long-Term Follow-Up Study Examining Clinical and Genetic Predictors Of Radiographic Sacroiliitis
Background/Purpose: Psoriatic arthritis (PsA) is characterised by involvement of both the appendicular and axial skeleton. Little is known about the clinical predictors of sacroiliitis (SI),…Abstract Number: L10 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Patients with Active Psoriatic Arthritis: 2-Year Results from a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Background/Purpose: To evaluate long-term clinical/radiographic efficacy of subcutaneous UST 45/90 mg in patients with active psoriatic arthritis (PsA) through wk108 of the PSUMMIT 1 trial.…Abstract Number: 2478 • 2013 ACR/ARHP Annual Meeting
Clinical Characteristics Of Patients With Early Spondyloarthritis. Results From a Specialized Consultation In a Clinical Hospital
Background/Purpose: The classification criteria for spondyloarthritis (SpA) intend to identify patients with this disease from the initial stages. The nonspecific characteristics, symptoms, signs, and additional…Abstract Number: 528 • 2013 ACR/ARHP Annual Meeting
Upregulated Th17 and Innate Pathways Are More Characteristic Of The Skin Than The Synovium In Psoriatic Arthritis
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory joint disease associated with psoriasis. There is little understanding of the relative levels of cytokines and chemokines between…Abstract Number: 2486 • 2013 ACR/ARHP Annual Meeting
Clinical Performance Of 4 Methods For Detecting Latent Tuberculosis Infection (LTbI) In Patients With Active Chronic Inflammatory Arthritis Taking TNFα Blockers
Background/Purpose: About 5% of the Brazilian population has some chronic inflammatory arthropathy (CIA), including rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PA) and juvenile…Abstract Number: 344 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotype Of Patients With Arthritis Mutilans Has Important Differences Compared To Other Patients With Psoriatic Arthritis
Background/Purpose: Arthritis mutilans (AM), a severe form of psoriatic arthritis (PsA), is characterised clinically by digital shortening resulting from osteolysis and/or erosions. It is still…Abstract Number: 1348 • 2012 ACR/ARHP Annual Meeting
Diffuse Idiopathic Skeletal Hyperostosis (DISH) in Psoriatic Arthritis
Background/Purpose: Spondylitis in Psoriatic Arthritis (PsA) sometimes resembles DISH because of the presence of juxta-vertebral calcification that resemble syndesmophytes. Distinguishing spondylitis from DISH has therapeutic…Abstract Number: 1044 • 2012 ACR/ARHP Annual Meeting
Ultrasound Scores of Enthesitis and Dactylitis Do Not Correlate with Corresponding Clinical Findings in Psoriasis Arthritis
Background/Purpose: To compare sonography verified inflammation of entheses, tendons and joints with corresponding clinical findings in psoriasis arthritis (PsA) patients. Methods: Prospective study of 70 consecutive…Abstract Number: 1002 • 2012 ACR/ARHP Annual Meeting
Microrna Expression Profiles in Peripheral Blood Mononuclear Cells of Early Onset Psoriatic Arthritis
Background/Purpose: Micro-RNAs (miRNAs) are small non-coding RNAs that negatively regulate gene expression. It is known that an altered miRNA expression plays an important role in…Abstract Number: 573 • 2012 ACR/ARHP Annual Meeting
Differential Association Between Human Leukocyte Antigen (HLA) Alleles and Joint Subluxation and Ankylosis in Patients with Psoriatic Arthritis
Background/Purpose: We have previously reported the association between HLA and KIR gene variants with the development of Arthritis Mutilans (AM) in psoriatic arthritis (PsA). However,…
ACR Meeting Abstracts